Abstract
In early January 2022, FDA released a Drug Safety Communication surrounding dental problems following use of buccal and sublingual buprenorphine products for the treatment of pain and opioid use disorder.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
